Armouring anti-cancer T cells against immunosuppressants

January 18, 2021

SINGAPORE, 19 January 2021 - Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armoured immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant drugs patients take to avoid organ rejection. The findings were published in the journal Hepatology.

Hepatocellular carcinoma is the most common type of primary liver cancer and the sixth most common cancer worldwide. It often develops in people with chronic liver disease following hepatitis B infection.

A common treatment for hepatocellular carcinoma is to completely remove the liver and replace it with a healthy one from a donor. However, hepatitis B-related hepatocellular carcinoma can recur in some patients following transplantation. To kill the cancer, doctors can inject immune cells, called T cells, which are specially designed to target hepatitis B material found in the cancer cells. However, liver transplant patients must take drugs that suppress their immune systems to prevent their bodies from attacking the transplants. This significantly hinders the effectiveness of T cell therapy.

"We developed a method to make T cells that specifically target the hepatitis B antigen in liver cancer cells while, at the same time, making them resistant to two commonly used immunosuppressants: tacrolimus and mycophenolate mofetil," said Professor Antonio Bertoletti, senior author of the study from Duke-NUS' Emerging Infectious Diseases Programme.

"Importantly, the resistance of our T cells to the immunosuppressants only lasted for about four days after which they regain their sensitivity to the drugs," added Prof Bertoletti.

This transient effect, a result of the engineering approach the team used, provides an additional layer of safety to minimise the possibility of organ rejection.

Prof Bertoletti and his colleagues began their investigations by testing the effects of tacrolimus and mycophenolate mofetil on T cells designed with a special receptor that targets hepatitis B antigens located on liver cancer cells. They found that both drugs significantly reduced the T cells' ability to kill the cancer cells.

The team then re-designed the T cells by adding genetic codes that disrupt the enzymes needed by the two drugs to suppress immune cells. They found that these 'immunosuppressive drug resistant armoured hepatitis B T cell receptor' (IDRA HBV-TCR) T cells showed "superior killing" power of hepatocellular carcinoma cell targets for up to four days.

"We also found that this strategy can be applied to target other pathologies that commonly occur in transplant patients receiving immunosuppressive drugs, like Epstein-Barr virus and cytomegalovirus reactivations," said Dr Anthony T Tan, a senior research fellow in Prof Bertoletti's lab and a co-author of the study.

"Innovative research like this lays the foundation for new discoveries and transformative change," said Professor Patrick Casey, Senior Vice-Dean for Research, Duke-NUS Medical School. "With waiting lists for organs lengthening around the world, ensuring that those patients who benefit from a much-needed transplant can remain in remission is a significant advance and offers much hope."

The team next aims to apply their approach in clinical trials.
-end-


Duke-NUS Medical School

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.